Hyderabad-based Suven Life Sciences has reported positive topline results from its Phase 2b proof-of-concept trial of Ropanicant in patients with Major Depressive Disorder (MDD), marking a key milestone in its clinical pipeline.

 

The study met its primary endpoint. Patients receiving Ropanicant 45 mg twice daily showed a clinically meaningful improvement in Montgomery–Asberg Depression Rating Scale (MADRS) scores at Week 6 compared with placebo.

 

Company data highlighted that a ~2-point difference on the MADRS scale is generally considered clinically meaningful, placing the observed effect above that threshold.

 

Secondary endpoints also showed supportive signals, including improvements in Clinical Global Impression–Severity (CGI-S), Sheehan Disability Scale (SDS), and the exploratory Quality of Life in Depression Scale (QLDS). Improvements in anhedonia were observed to correlate with gains in functioning and quality of life.

 

Safety outcomes were broadly reassuring. The company reported no withdrawal symptoms after discontinuation and no evidence of dissociation. Treatment-emergent adverse events were mostly mild to moderate, with no unexpected safety signals. There were no clinically meaningful changes in laboratory parameters, ECGs, vital signs, or physical examinations.

 

The study was a randomized, double-blind, placebo-controlled Phase 2b trial conducted across 35 sites in the United States, enrolling 214 patients over six weeks.

 

Suven has already begun planning a global Phase 3 registrational program for MDD based on the results.

 

Chairman and Managing Director Venkat Jasti said: "We are very excited to announce Ropanicant Phase-2b outcome, demonstrating clinically meaningful treatment benefits highlighting Ropanicant potential as a promising treatment for MDD. 

 

"There is still a significant unmet medical need despite the availability of multiple approved therapies for MDD. We strongly believe that Ropanicant would offer differentiated treatment option to meet the unmet medical need."

 

President and CSO Ramakrishna Nirogi added: “MDD is the leading cause of disability worldwide, and approximately 50% of patients do not adequately benefit from standard first-line antidepressant therapies. The Phase-2b data strongly supports the potential of Ropanicant as a promising treatment for MDD. We look forward to engaging with regulatory authorities worldwide to discuss Phase-3 clinical development plans of Ropanicant."

 

Ropanicant is a selective nicotinic α4β2 receptor antagonist being developed for MDD, with earlier Phase 1 and Phase 2a studies showing tolerability and antidepressant effects. Suven retains global intellectual property rights for the molecule and continues advancing multiple CNS programs across its pipeline.